Ian Clements

Ian Clements, listed as finance chief, appears in our data through filings on Mirum Pharmaceuticals, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 6 September 2019 to 10 November 2022, the count stands at 15 filings.

Market trades split into 7 purchases (€122k) and 1 sale (€26k). Netting one side against the other leaves €96k of net buying. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 7 share grants.

In size, the median ticket on the buying side is €18k. Clusters matter here: 7 out of 7 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.

Most recently, on 14 November 2022, the filings show a share grant worth €5,531 in Mirum Pharmaceuticals, Inc. The last insider purchase was made public on 29 November 2021, 1,789 days ago. Typically, a trade is published a median of 4 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.